Clinical trials: Portal Hypertension, active
Portal Hypertension, Hepatic Decompensation
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or…
- Conditions
- Portal Hypertension, Hepatic Decompensation, Advanced Chronic Liver Disease
- Trial name
- BB_cACLD (NCT06449339)
- Testing
- Carvedilol
- Where
- Hong Kong
- Volunteers
- 474 people
- Sponsor
- Chinese University of Hong Kong
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Cirrhosis
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation.
- Trial name
- Ant-TIPS (NCT07889726)
- Testing
- TIPS, Standard of Care (SOC)
- Where
- 8 sites in France
- Volunteers
- 266 people
- Sponsor
- University Hospital, Toulouse
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
This prospective observational study evaluates whether endohepatology changes treatment indications in adults at high risk of metabolic dysfunction-associated steatotic liver disease.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Liver Fibrosis, Portal Hypertension
- Trial name
- ENDO-MASH (NCT07877272)
- Testing
- Non-invasive MASLD and portal hypertension assessment, Single-session endohepatology assessment
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Muenster
Decompensated Cirrhosis
Risk Stratification for Adverse Events in End-Stage Liver Disease
Study Goal The goal of this multicenter, prospective observational cohort study is to develop and validate a multimodal predictive model that integrates portal hypertension, inflammation, and liver function indicators to predict…
- Trial name
- D-TECT (NCT07880678)
- Testing
- Routine Clinical Care with Biospecimen Collection and Free MRE Testing
- Volunteers
- 2,235 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Portal Hypertension, Chronic Liver Disease
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
This prospective multicentre observational reliability study will determine how much a repeated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement differs from the first measurement in the same patient…
- Conditions
- Portal Hypertension, Chronic Liver Disease, Liver Cirrhosis
- Trial name
- REPEAT-PPG (NCT07877298)
- Testing
- Repeated EUS-Guided Portal Pressure Gradient Measurement
- Where
- 5 sites in Belgium, Canada and 2 more
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cirrhosis, Hepatic Cell Carcinoma
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols.
- Conditions
- Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
- Trial name
- NCT06265272
- Testing
- Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Massachusetts General Hospital
Hypertension, Portal, Interventional Radiology
Percutaneous Portal Vein Recanalization for Refractory Portal Hypertension in Children With Non-Cirrhotic Extrahepatic Portal Vein Obstruction
This monocentric, prospective, observational study aims to evaluate the clinical efficacy, safety, and technical success of percutaneous portal vein recanalization (PVR) performed via interventional radiology.
- Conditions
- Hypertension, Portal, Interventional Radiology, Percutaneous Portal Vein Recanalization (PVR), Extrahepatic Portal Vein Obstruction (EHPVO)
- Trial name
- PRIMO-01 (NCT07873021)
- Testing
- Percutaneous Portal Vein Recanalization (PVR)
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- Papa Giovanni XXIII Hospital
Cirrhosis, Portal Hypertension
4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis
PORTAL-4D is a prospective, interventional, non-randomized, parallel-group diagnostic study conducted at Pitié-Salpêtrière Hospital (Paris, France).
- Trial name
- PORTAL-4D (NCT07554183)
- Testing
- 4D-Flow Liver and heart MRI with Gadolinium injection, Samples Without DNA
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ascites, Variceal Bleeding
VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)
This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension.
- Conditions
- Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
- Trial name
- VIATIPS (NCT07390344)
- Testing
- GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm)
- Where
- 3 sites in United States
- Volunteers
- 152 people
- Sponsor
- W.L.Gore & Associates
Liver Diseases, Portal Hypertension
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB).
- Trial name
- NCT05470205
- Testing
- SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 660 people
- Sponsor
- Thomas Jefferson University
Compensated Liver Disease, Esophageal Varices
Baveno VIII Criteria for Portal Hypertension in Egyptian Patients
This prospective observational study aims to validate Baveno VIII criteria for detection of clinically significant portal hypertension and to evaluate additional predictors of esophageal varices in Egyptian patients with…
- Conditions
- Compensated Liver Disease, Esophageal Varices, Portal Hypertension, Chronic Liver Disease
- Trial name
- NCT07842666
- Volunteers
- 125 people
- Sponsor
- Assiut University
Portal Hypertension, Cirrhosis
Noninvasive Prediction of Portal Hypertension in Cirrhosis Using Sound Touch Viscoelastography
The objective of this observational study is to investigate and validate the utility of the Sound Touch Viscoelastography(STVi) technique in patients with liver cirrhosis for noninvasive prediction of Portal hypertension (PH).
- Trial name
- NCT06316869
- Testing
- ultrasound test
- Where
- China
- Volunteers
- 216 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Liver Cirrhosis, Portal Hypertension
Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis
1. Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis.
- Trial name
- NCT07116096
- Testing
- Jamar Hand Dynamometer, Hand Dynamometer
- Where
- 2 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanxi Provincial People's Hospital
Portal Hypertension, Chronic Liver Disease (CLD)
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative…
- Conditions
- Portal Hypertension, Chronic Liver Disease (CLD), Cirrhosis
- Trial name
- EUS-PPG (NCT06863012)
- Testing
- Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Measurement
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
Hepatic Encephalopathy, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Coil-Assisted Small-Diameter Covered-Stent Shunt Reduction for Refractory Hepatic Encephalopathy After TIPS
Refractory hepatic encephalopathy (RHE) after transjugular intrahepatic portosystemic shunt (TIPS) is a serious complication that can markedly impair quality of life and worsen prognosis.
- Conditions
- Hepatic Encephalopathy, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Portal Hypertension, Liver Cirrhosis
- Trial name
- NCT07799948
- Testing
- Coil-assisted Small-diameter Stent Shunt reduction
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Air Force Military Medical University, China
Cirrhosis, Portal Hypertension
Body-weight Reduction Effect on Portal Hypertension in Compensated Cirrhosis
Obesity and metabolic abnormalities accelerate decompensation in compensated cirrhosis, driven by clinically significant portal hypertension (CSPH, HVPG≥10 mmHg).
- Conditions
- Cirrhosis, Portal Hypertension, Fatty Liver Disease, GLP-1
- Trial name
- B-REACH (NCT07797101)
- Testing
- Mazdutide injection
- Volunteers
- 50 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Portal Hypertension, TIPS
The BD Liverty™ TIPS Stent Graft Study
The objective of the study is to assess the safety and effectiveness of the BD Liverty™ TIPS Stent Graft for the treatment of the complications of portal hypertension from cirrhosis.
- Trial name
- ARCH (NCT05711316)
- Testing
- BD Liverty™ TIPS Stent Graft
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 177 people
- Sponsor
- C. R. Bard
Chronic Liver Disease and Cirrhosis, Chronic Liver Disease
hepatomiR cACLD Study
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic…
- Conditions
- Chronic Liver Disease and Cirrhosis, Chronic Liver Disease, Portal Hypertension
- Trial name
- NCT06432582
- Testing
- hepatomiR
- Where
- Austria
- Volunteers
- 156 people
- Sponsor
- Karl Landsteiner University of Health Sciences